Akebia Grants Options for 679,900 Inducement Shares

The $1.39 exercise price matches the March 31 close, with the awards vesting over four years for 13 new employees.

Apr. 2, 2026 at 8:05pm

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring medical equipment and supplies, symbolizing Akebia's focus on developing innovative treatments for kidney disease.Akebia's new stock options aim to attract top talent to advance treatments for kidney disease.Cambridge Today

Akebia Therapeutics, a biopharmaceutical company focused on kidney disease, has granted stock options to 13 newly hired employees. The options, which total 679,900 shares, have an exercise price of $1.39 per share and vest over a four-year period, tying the new hires to the company under Nasdaq rules.

Why it matters

The inducement grants are a common practice for publicly traded companies to attract and retain talent, especially in competitive fields like biotech. Akebia's move signals its commitment to expanding its workforce to further its mission of improving the lives of people impacted by kidney disease.

The details

The stock options were granted on March 31, 2026 in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of $1.39 per share matches Akebia's closing price on the grant date. The options will vest over four years, with 25% of the shares vesting on the first anniversary and the remaining 75% vesting quarterly thereafter, subject to the new employees' continued service with the company.

  • The stock options were granted on March 31, 2026.
  • The options will vest over a four-year period, with 25% vesting on the first anniversary and the remaining 75% vesting quarterly thereafter.

The players

Akebia Therapeutics

A biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Mercedes Carrasco

An employee at Akebia Therapeutics.

Got photos? Submit your photos here. ›

The takeaway

Akebia's inducement grants demonstrate its commitment to expanding its workforce and furthering its mission of improving the lives of people impacted by kidney disease. The options, which tie new hires to the company for four years, are a common practice for publicly traded companies looking to attract and retain top talent in competitive fields.